Institute For Clinical Pharmacodynamics, Inc.

Institute For Clinical Pharmacodynamics, Inc., a minority-owned, for-profit organization based in Schenectady, New York, operates as a prime contractor providing pharmacometric analysis, preclinical infectious disease modeling, and regulatory science research to the Department of Health and Human Services (HHS) — primarily the Food and Drug Administration (FDA) and the National Institute of Allergy and Infectious Diseases (NIAID). The vendor competes full-and-open with no set-aside designations across its federal footprint.

ICPI's customer concentration is heavily weighted toward HHS, which accounts for 100% of awards. The FDA dominates by award count with five definitive contracts valued at $1.4 million combined potential value, while NIAID anchors the portfolio's dollar value with a single $146.3 million Indefinite Delivery Contract. This split reflects radically different deal structures: FDA work flows through small research contracts responsive to Broad Agency Announcements in antibiotic susceptibility guidance and the Combatting Antibiotic Resistant Bacteria (CARB) program, while NIAID work is placed under a multi-year IDC for preclinical models of infectious diseases. The ranking divergence is acute — NIAID's single award represents 99% of combined potential value, while FDA's five awards represent 1%.

ICPI's FDA contract work centers on pharmacometric approaches to developing modernized susceptibility guidance for antibiotic compounds, including daptomycin and enterococcus species ($325 thousand awarded August 2026, running through July 2027), nitrofurantoin dosing using dynamic urinary tract in vitro infection modeling ($248.6 thousand awarded August 2024, completed October 2025), ampicillin and vancomycin for Enterococcus species ($263 thousand awarded September 2023), sulfamethoxazole-trimethoprim ($291.1 thousand awarded September 2022), and related CARB program research ($291.6 thousand awarded September 2022). The NIAID IDC, awarded July 2024 and running through July 2031 under Task Area C, tasks ICPI with providing pre-clinical models of infectious diseases, including animal model studies, pathogen production and characterization, and evaluation of candidate countermeasures against RNA viruses with pandemic potential, antimicrobial-resistant infections, and emerging pathogens on NIAID's list.

Activity across the source data spans four years at a modest cadence — two awards in 2022, one in 2023, two in 2024, and one in 2026 — with one award (the FDA daptomycin contract, $325 thousand) facing completion inside the next twenty-four months and therefore subject to recompete. ICPI operates as a pure prime across all federal work, with no subcontractor role in the source data. Service Contract Inventory reporting shows minimal invoiced revenue on federal service contracts above the $150,000 threshold ($0 reported across FY2022–FY2024), suggesting that ICPI's FDA work flows through research contracts (which fall outside SCI's service-contract scope) and that the NIAID IDC remains in early execution phase. ICPI's primary NAICS and PSC framing centers on research and development in biotechnology (NAICS 541714) and health R&D services (PSC AJ11), reflecting a focused mission in regulatory science and preclinical infectious disease research for HHS.